Yifeng Pharmacy (603939) Fair Value & Analysis

Healthcare · CN · Market cap 28.4B CNY (≈ $4.2B) · ISIN CNE100001TS5

What is Yifeng Pharmacy really worth?

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

What matters now

• Solid quality (63/100) at a price below fair value, the discount is the argument here, not the business quality.
• The price sits in the lower half of our model range, the side with the larger margin of safety.
• The data supports the verdict: every model runs on fully documented inputs.

Price vs Fair Value (5 years)

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 5, 2026.

How to read this chart

60‑month range ¥17.75 – ¥49.97 · fair‑value band ¥21.80 – ¥36.34 · the ¥22.90 price screens below the ¥29.07 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 5, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Yifeng Pharmacy (603939) currently trades at ¥22.90, while our model-based Fair Value estimate is ¥29.07, implying the stock looks roughly 21.2% undervalued today. The Quality Score stands at 63/100 (solid quality), in the Healthcare sector. Bull case: the DCF Models group reads highest at a median of ¥60.94 per share, and 21 of the 26 models we run sit above the ¥22.90 price. Bear case: the Asset-Based group reads lowest at ¥6.43, and 5 of the 26 models stay below the price. Evidence for this calculation is high.

Over the trailing twelve months, Yifeng Pharmacy generated revenue of 24.5B CNY at a net margin of 7.1%. Revenue grew 1.3% year over year. It earns a return on equity of 15.2%. Net debt stands at 365M CNY. Fundamentals as of Sep 5, 2026

Our scenario range runs from ¥21.80 (bear case) to ¥36.34 (bull case); at ¥22.90, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 14% below its 52-week high and 17% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at −21% fair-value upside, at 27%, 603939 screens cheaper than that median.

Fair Value models

This estimate rests on fiscal year 2025 figures, and about 8 months have passed since. In that time the company retained roughly ¥0.4737 per share, which is 1.6 % of the fair value. The fair value deliberately does not add this in: the models value reported figures, not a projection.

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted, family-balanced blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small. Every input is real reported data, nothing guessed.

Widest divergence: DCF Models (¥60.94) versus Asset-Based (¥6.43). Highest evidence: FCF DCF (75).

Key figures & financial health

Quality Score breakdown

About the company

Yifeng Pharmacy Chain Co., Ltd. engages in the retail business of pharmaceutical products in China. The company operates through Retail business and Wholesale business segments.

Full company description

Yifeng Pharmacy Chain Co., Ltd. engages in the retail business of pharmaceutical products in China. The company operates through Retail business and Wholesale business segments. The company offers Western and Chinese patent medicine, traditional Chinese medicine herbal pieces, medical devices and equipment, health supplements and products, personal care products, drugs, and convenience products related to health. It is also involved in chronic disease management, medical project investment, and medical technology development, as well as operates internet hospitals and clinics. The company also offers its products through franchise distribution and e-commerce. Yifeng Pharmacy Chain Co., Ltd. was founded in 2001 and is headquartered in Changsha, China.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

Yifeng Pharmacy reported revenue of 24.4B CNY in FY2025 versus 15.3B CNY in FY2021, a compound +12.4%/yr. Reported net income was 1.7B CNY in FY2025, compounding +17.3%/yr from FY2021.

Watch 603939: get an alert when its fair value changes →

Peer Group

Pharmaceutical Retailers · 57 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Valuation Multiples vs Pharmaceutical Retailers median · lower = cheaper

Strength profile in five axes (Snowflake)

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

Similar stocks

10 more Pharmaceutical Retailers stocks, each showing price versus our Fair Value estimate (as of Sep 5, 2026).

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

Discover tools

Frequently asked questions